Drug Discovery Market Research Reports & Industry Analysis
Drug discovery is the systematic process of identifying, designing, and developing new pharmaceutical compounds or therapies to treat specific diseases or medical conditions. This is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will yield products that achieve regulatory approval by the Food & Drug Administration (FDA). To help stakeholders navigate this complex market, MarketResearch.com offers a suite of comprehensive drug discovery reports on industries big and small.
Understanding the Drug Discovery Market
- Our compilation of reports features thousands of reports from leading research firms, allowing you to access highly targeted information.
- We provide a rich repository of data, including analysis of drug discovery market trends, forecasts, growth opportunities, and strategies.
- We also provide expert commentary on disruptive technologies and the use of artificial intelligence, machine learning, and blockchain in drug discovery.
Informed Insights: Your Path to Success
Whether you're an industry professional, a consultant, or an executive, our research collection provides credible data to help you make informed decisions that catalyze growth. For decades, we have served top pharmaceutical companies, investment banks, and consulting firms as a trusted research partner. Uncover new opportunities and stay ahead of the curve with MarketResearch.com's drug discovery industry reports.
Drug Discovery Industry Research & Market Reports
-
Alzheimer’s Therapeutics Market By Drug Class (Cholinesterase inhibitors, N-Methyl-D-Aspartate (NMDA) receptor antagonist, Others), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031
... therapeutics market was valued $6,123 million in 2021 and expected to reach $13017.93 million by 2031, with a CAGR of 8.1% from 2022 to 2031. Alzheimer’s disease is a brain disorder, which slowly destroys memory ... Read More
-
VRAYLAR Emerging Drug Insight and Market Forecast – 2032
... of the VRAYLAR for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along ... Read More
-
LOU064 Emerging Drug Insight and Market Forecast − 2032
... of the LOU064 for Chronic Spontaneous Urticaria in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along ... Read More
-
Urticaria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... than 80 million diagnosed prevalent cases of urticaria across 16 pharmaceutical markets. Most of the leading marketed drugs for urticaria are second-generation H1-antihistamines, which are used as the first-line symptomatic treatment for the disease. Out ... Read More
-
Methicillin-Resistant Staphylococcus Aureus (MRSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... will be more than 859,000 incident cases of MRSA across seven major pharmaceutical markets. There are eight leading marketed drugs for the treatment of MRSA; Pfizer is a key player in the disease space. R&D ... Read More
-
Fungal Infections Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
... be more than three million incident cases of fungal Infections across 16 pharmaceutical markets. There are several marketed innovator drugs for the treatment of fungal infections, mostly cytochrome P450 and beta glucan synthase enzyme inhibitors. ... Read More
-
Rabies Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Rabies (Infectious Disease) pipeline landscape. Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of ... Read More
-
Essential Thrombocythemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Essential Thrombocythemia (Oncology) pipeline landscape. Essential thrombocythemia is a chronic myeloproliferative neoplasm in which cells in the bone marrow that produce the blood cells develop and function abnormally. In essential ... Read More
-
Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Osteoporosis (Metabolic Disorders) pipeline landscape. Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or ... Read More
-
Cathepsin L1 (Cathepsin L or Major Excreted Protein or CTSL or EC 3.4.22.15) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... L or Major Excreted Protein or CTSL or EC 3.4.22.15) - Cathepsin L, a lysosomal endopeptidase is a member of the papain-like family of cysteine proteinases. Cathepsin L plays a major role in antigen processing, ... Read More
-
Corneal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape. Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors ... Read More
-
Ventricular Tachycardia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Ventricular Tachycardia (Cardiovascular) pipeline landscape. Ventricular tachycardia is a very fast heart rhythm that begins in the ventricles. Symptoms of ventricular tachycardia include dizziness, fainting, fatigue, chest pain and shortness ... Read More
-
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Drugs In Development, 2022, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape. Peripheral vascular disease (PVD) refers to diseases ... Read More
-
Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 'Collagenase 3 - Drugs In Development, 2022'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and ... Read More
-
Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... the recently published report 'Histone Deacetylase 6 - Drugs In Development, 2022'; Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC 3.5.1.98) pipeline Target constitutes close to 53 molecules. Out of ... Read More
-
Idiopathic Pulmonary Fibrosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape. Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung ... Read More
-
Bronchiectasis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Bronchiectasis (Respiratory) pipeline landscape. Bronchiectasis is a chronic condition where the walls of the bronchial tubes are permanently damaged. These damage allow bacteria and mucus to build up in lungs. Bronchiectasis is ... Read More
-
Hypertrophic Cardiomyopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Hypertrophic Cardiomyopathy (Cardiovascular) pipeline landscape. Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickened heart muscles make it harder for the ... Read More
-
Atherosclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... overview of the Atherosclerosis (Cardiovascular) pipeline landscape. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The ... Read More
-
Head and Neck Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Drugs In Development, 2022, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape. Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, ... Read More
-
Oropharyngeal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape. Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the ... Read More
-
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Development, 2022, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape. Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries ... Read More
-
Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... 2022 Update Summary Retinoic Acid Receptor Alpha (RAR Alpha or Nuclear Receptor Subfamily 1 Group B Member 1 or NR1B1 or RARA) - Retinoic acid receptor alpha (RARA) is a nuclear receptor that is encoded ... Read More
-
Cathepsin B (APP Secretase or Cathepsin B1 or CTSB or EC 3.4.22.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... or Cathepsin B1 or CTSB or EC 3.4.22.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The latest report Cathepsin B ... Read More
-
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
... Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating ... Read More
Research Assistance
